Case Reports of TFE3-Rearranged Renal Cell Carcinoma: FDG-PET Uptake Might Help Diagnosis

Overview

Journal J Kidney Cancer VHL

Date 2023 Oct 4

PMID 37789903

Authors

Sho Murakami

Keita Nagawa

Takanori Inui

Aya Yamamoto

Mizuka Suzuki

Fumitaka Koga

Toru Motoi

Yasunobu Takaki

Affiliations

Soon will be listed here.

Abstract

Translocation and transcription factor E3 (TFE3)-rearranged renal cell carcinoma (RCC) is a rare subtype of RCCs characterised by the fusion of the TFE3 transcription factor genes on chromosome Xp11.2 with one of the multiple genes. TFE3-rearranged RCC occurs mainly in children and adolescents, although middle-aged cases are also observed. As computed tomography (CT)/magnetic resonance imaging (MRI) findings of TFE3-rearranged RCC overlap with those of other RCCs, differential diagnosis is often challenging. In the present case reports, we highlighted the features of the fluorine-18-labelled fluorodeoxyglucose positron emission tomography with CT (FDG PET-CT) in TFE3-rearranged RCCs. Due to the rarity of the disease, FDG PET-CT features of TFE3-rearranged RCC have not yet been reported. In our cases, FDG PET-CT showed high standardised uptake values (SUVmax) of 7.14 and 6.25 for primary tumours. This might imply that TFE3-rearranged RCC has high malignant potential. This is conceivable when the molecular background of the disease is considered in terms of glucose metabolism. Our cases suggest that a high SUVmax of the primary tumour is a clinical characteristic of TFE3-rearranged RCCs.

Citing Articles

Approach to Diagnosis of TFE3-rearranged Renal Cell Carcinoma in a Limited Resource Setting: A Case Report.

Pagarigan A, Reyes-Murillo P, Carbonell D J Kidney Cancer VHL. 2024; 11(3):40-44.

PMID: 39206137 PMC: 11350386. DOI: 10.15586/jkcvhl.v11i3.338.

References

Raj S, Kesari K, Kumar A, Rathi B, Sharma A, Gupta P . Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer. 2022; 21(1):31. PMC: 8790852. DOI: 10.1186/s12943-022-01503-1. View

Zhou J, Zhao L, Yang Z, Chen Y, Wu X, Xue W . Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas. BMC Urol. 2022; 22(1):109. PMC: 9295427. DOI: 10.1186/s12894-022-01060-1. View

Masago T, Kobayakawa S, Ohtani Y, Taniguchi K, Naka T, Kuroda N . Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review. Int Cancer Conf J. 2020; 9(4):182-186. PMC: 7450002. DOI: 10.1007/s13691-020-00430-6. View

Woo S, Kim S, Lee M, Moon K, Kim S, Cho J . MDCT findings of renal cell carcinoma associated with Xp11.2 translocation and TFE3 gene fusion and papillary renal cell carcinoma. AJR Am J Roentgenol. 2015; 204(3):542-9. DOI: 10.2214/AJR.14.12950. View

Macher-Goeppinger S, Keith M, Endris V, Penzel R, Tagscherer K, Pahernik S . MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget. 2016; 8(1):1046-1057. PMC: 5352033. DOI: 10.18632/oncotarget.13540. View

Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B . Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int. 2007; 101(4):480-4. DOI: 10.1111/j.1464-410X.2007.07238.x. View

Wang H, Ding H, Chen J, Chao C, Lu Y, Lin W . Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012; 12:464-74. PMC: 3483599. DOI: 10.1102/1470-7330.2012.0042. View

Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T . Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med. 2015; 40(12):936-40. PMC: 4890815. DOI: 10.1097/RLU.0000000000000875. View

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z . 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49(5):798-805. DOI: 10.1016/j.eururo.2005.11.035. View

10.

Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S . Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009; 15(4):1170-6. DOI: 10.1158/1078-0432.CCR-08-1183. View

11.

Liu Y . The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations. Front Oncol. 2016; 6:201. PMC: 5012103. DOI: 10.3389/fonc.2016.00201. View

12.

Calio A, Segala D, Munari E, Brunelli M, Martignoni G . MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. Cancers (Basel). 2019; 11(8). PMC: 6721505. DOI: 10.3390/cancers11081110. View

13.

Koie T, Yoneyama T, Hashimoto Y, Kamimura N, Kusumi T, Kijima H . An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man. Int J Urol. 2009; 16(3):333-5. DOI: 10.1111/j.1442-2042.2008.02231.x. View

14.

Chung E, Lattin Jr G, Fagen K, Kim A, Pavio M, Fehringer A . Renal Tumors of Childhood: Radiologic-Pathologic Correlation Part 2. The 2nd Decade: From the Radiologic Pathology Archives. Radiographics. 2017; 37(5):1538-1558. PMC: 5621729. DOI: 10.1148/rg.2017160189. View

15.

Hou G, Zhao D, Jiang Y, Zhu Z, Huo L, Li F . Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Cancer Imaging. 2021; 21(1):25. PMC: 7908760. DOI: 10.1186/s40644-021-00393-8. View

16.

Anton Aparicio L, Villaamil V, Calvo M, Rubira L, Rois J, Valladares-Ayerbes M . Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters. Mol Med Rep. 2011; 3(4):575-80. DOI: 10.3892/mmr_00000300. View

17.

Cheng X, Gan W, Zhang G, Li X, Guo H . Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies. BMC Urol. 2016; 16(1):40. PMC: 4940698. DOI: 10.1186/s12894-016-0154-6. View

18.

Armah H, Parwani A . Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med. 2010; 134(1):124-9. DOI: 10.5858/2008-0391-RSR.1. View